BOSTON – New data on Regulus Therapeutics Inc.’s RNA interference drug RG-101, which had been submitted for presentation at the American Association for the Study of Liver Diseases meeting, show that the Phase II candidate has the efficacy to help it find a commercially viable route into the hepatitis C market, if the company can get past a clinical hold placed by FDA earlier this year.
The Phase II data showing that RG-101 in combination with direct-acting antiviral (DAA) therapy can reduce duration of treatment for...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
